BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30442928)

  • 1. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.
    Ravi P; Kumar SK; Roeker L; Gonsalves W; Buadi F; Lacy MQ; Go RS; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
    Blood Cancer J; 2018 Nov; 8(12):116. PubMed ID: 30442928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party.
    Jung SH; Kim K; Yoon SE; Moon JH; Kim D; Kim HJ; Kim MK; Kim KH; Lee HJ; Lee JH; Kim SH; Yoo KH; Lee JH; Lee JJ
    Blood Cancer J; 2022 Nov; 12(11):157. PubMed ID: 36404323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.
    Evans LA; Jevremovic D; Nandakumar B; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Go R; Russell S; Lust JA; Lin Y; Siddiqui M; Kyle RA; Gertz MA; Rajkumar SV; Kumar SK; Gonsalves WI
    Am J Hematol; 2020 Jun; 95(6):637-642. PubMed ID: 32129510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.
    Granell M; Calvo X; Garcia-Guiñón A; Escoda L; Abella E; Martínez CM; Teixidó M; Gimenez MT; Senín A; Sanz P; Campoy D; Vicent A; Arenillas L; Rosiñol L; Sierra J; Bladé J; de Larrea CF;
    Haematologica; 2017 Jun; 102(6):1099-1104. PubMed ID: 28255016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China.
    Peijing Q; Yan X; Yafei W; Dehui Z; Zengjun L; Junyuan Q; Yaozhong Z; Lugui Q
    Acta Haematol; 2009; 121(1):47-51. PubMed ID: 19339770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
    Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Siddiqui M; Go RS; Jevremovic D; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
    Mayo Clin Proc; 2021 Mar; 96(3):677-687. PubMed ID: 33673918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.
    Nahi H; Genell A; Wålinder G; Uttervall K; Juliusson G; Karin F; Hansson M; Svensson R; Linder O; Carlson K; Björkstrand B; Kristinsson SY; Mellqvist UH; Blimark C; Turesson I
    Eur J Haematol; 2017 Sep; 99(3):216-222. PubMed ID: 28544116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell leukemia masquerading as ALL-L3--a case report.
    Tripathy K; Gouda KP; Chakrabarty S; Das AK; Mohanty R
    Indian J Pathol Microbiol; 2005 Apr; 48(2):221-3. PubMed ID: 16758674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
    Fernández de Larrea C; Kyle RA; Durie BG; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; LeLeu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist UH; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Bladé J; Orlowski RZ; Shah JJ;
    Leukemia; 2013 Apr; 27(4):780-91. PubMed ID: 23288300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Cell Leukemia: Definition, Presentation, and Treatment.
    Gundesen MT; Lund T; Moeller HEH; Abildgaard N
    Curr Oncol Rep; 2019 Jan; 21(1):8. PubMed ID: 30689121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
    Fernández de Larrea C; Kyle R; Rosiñol L; Paiva B; Engelhardt M; Usmani S; Caers J; Gonsalves W; Schjesvold F; Merlini G; Lentzch S; Ocio E; Garderet L; Moreau P; Sonneveld P; Badros A; Gahrton G; Goldschmidt H; Tuchman S; Einsele H; Durie B; Wirk B; Musto P; Hayden P; Kaiser M; Miguel JS; Bladé J; Rajkumar SV; Mateos MV
    Blood Cancer J; 2021 Dec; 11(12):192. PubMed ID: 34857730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
    Gonsalves WI; Rajkumar SV; Gupta V; Morice WG; Timm MM; Singh PP; Dispenzieri A; Buadi FK; Lacy MQ; Kapoor P; Gertz MA; Kumar SK
    Leukemia; 2014 Oct; 28(10):2060-5. PubMed ID: 24618735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell leukemia: update on biology and therapy.
    Mina R; D'Agostino M; Cerrato C; Gay F; Palumbo A
    Leuk Lymphoma; 2017 Jul; 58(7):1538-1547. PubMed ID: 27819179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
    Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
    Leuk Lymphoma; 2022 Dec; 63(12):2955-2964. PubMed ID: 35819882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
    Gonsalves WI; Rajkumar SV; Dispenzieri A; Dingli D; Timm MM; Morice WG; Lacy MQ; Buadi FK; Go RS; Leung N; Kapoor P; Hayman SR; Lust JA; Russell SJ; Zeldenrust SR; Hwa L; Kourelis TV; Kyle RA; Gertz MA; Kumar SK
    Leukemia; 2017 Jan; 31(1):130-135. PubMed ID: 27457702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of clonal circulating plasma cells in relapsed multiple myeloma.
    Gonsalves WI; Morice WG; Rajkumar V; Gupta V; Timm MM; Dispenzieri A; Buadi FK; Lacy MQ; Singh PP; Kapoor P; Gertz MA; Kumar SK
    Br J Haematol; 2014 Nov; 167(4):500-5. PubMed ID: 25113422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.